Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.87 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.83 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6552954 | 0.98 | MEN1 (1.00) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| Propane SCHEMBL8097570 | 0.96 | MEN1 (0.88) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| SCHEMBL22331586 | 0.94 | MEN1 (0.84) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| SCHEMBL680531 | 0.93 | L3MBTL1 (1.00) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| SCHEMBL18753914 | 0.92 | L3MBTL1 (0.81) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| SCHEMBL15766433 | 0.91 | SIGMAR1 (1.00) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| SCHEMBL19391367 | 0.91 | SIGMAR1 (1.00) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| SCHEMBL920070 | 0.91 | SIGMAR1 (1.00) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| SCHEMBL5911099 | 0.91 | SIGMAR1 (1.00) | MEN1KMT2AL3MBTL1SIGMAR1ATM | |
| SCHEMBL9149422 | 0.91 | SIGMAR1 (1.00) | MEN1KMT2AL3MBTL1SIGMAR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1019 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722187-A1 | BUILDING BLOCK FOR TRIFLUOROALKYLATION AND TRIFLUOROALKYLATION METHOD USING SAME | Seoul National University Hospital (KR) | 2026-04-08 | — | — | EP | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2024242479-A1 | BUILDING BLOCK FOR TRIFLUOROALKYLATION AND TRIFLUOROALKYLATION METHOD USING SAME | 서울대학교병원 | 2024-11-28 | — | — | WO | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| US-20230364224-A1 | Pharmaceutical Composition For Allergen Specific Immunotherapy | HOPITAUX UNIVERSITAIRES DE GENEVE (CH) | 2023-11-16 | — | — | US | claimed |
| EP-4213873-A1 | COMPOSITE SOLDER BALLS METALLISED ON THE SURFACE AND CALIBRATED FOR THE ASSEMBLY OF ELECTRONIC BOARDS | Hopitaux Universitaires de Genève (CH) | 2023-07-26 | — | — | EP | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000050406-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2000-08-31 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000037425-A1 | METHOD FOR PRODUCING FLUOXETIN | SIEGFRIED CMS AG (CH) | 2000-06-29 | — | — | WO | claimed |
| EP-0998934-A1 | REMEDIES FOR INTRAMEDULLARY DISEASES | TORAY INDUSTRIES, INC. (JP) | 2000-05-10 | — | — | EP | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| WO-1991019002-A1 | A PROCESS FOR CHIRAL ENRICHMENT OF ASYMMETRIC PRIMARY AMINES | CARLBIOTECH LTD. A/S (DK) | 1991-12-12 | — | — | WO | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | MEN1 1967/4885KMT2A 2781/4885L3MBTL1 1415/4885 |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | MEN1 1967/4885KMT2A 2781/4885L3MBTL1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.